Clarithromycin (Klacid MR 500 mg) and Upadacitinib: interaction and safety
This source-based reference is not a personal treatment recommendation. The relevance and management of an interaction depend on the exact products, route, dose and clinical situation.
Interaction mechanism
Systemic strong CYP3A4 inhibition can increase upadacitinib exposure.
Clinical significance and safety
Klacid MR 500 mg contains a systemic strong CYP3A4 inhibitor and can increase upadacitinib exposure and adverse-effect risk. Upadacitinib management differs by indication; close monitoring or a prescriber-directed modification may be required. Confirm the full regimen with the prescriber or pharmacist before coadministration.
Using this information
This is a source-based reference record, not a recommendation to combine, stop or change medicines. A missing interaction record does not establish safe use. A qualified healthcare professional should consider the exact products, doses, other medicines and individual health circumstances.